Cargando…

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome

We prospectively evaluated the frequency of natural resistance-associated substitutions (RASs) in the NS3 and NS5A regions according to different HCV genotypes and their possible effect on treatment outcome in HIV-1/HCV patients treated with direct-acting antivirals (DAAs). Baseline RASs in the NS3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagaglio, Sabrina, Hasson, Hamid, Peano, Luca, Vercesi, Riccardo, Messina, Emanuela, Galli, Andrea, Uberti-Foppa, Caterina, Morsica, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150799/ https://www.ncbi.nlm.nih.gov/pubmed/32121164 http://dx.doi.org/10.3390/v12030269

Ejemplares similares

Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates
por: Bagaglio, Sabrina, et al.
Publicado: (2018)

Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype
por: Morsica, Giulia, et al.
Publicado: (2021)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions
por: Bagaglio, Sabrina, et al.
Publicado: (2019)

Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment
por: Bagaglio, Sabrina, et al.
Publicado: (2016)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients
por: Morsica, Giulia, et al.
Publicado: (2022)

Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report
por: Bagaglio, Sabrina, et al.
Publicado: (2009)

Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy
por: Sagnelli, Caterina, et al.
Publicado: (2020)

Survival in People Living with HIV with or without Recurrence of Hepatocellular Carcinoma after Invasive Therapy
por: Bertoni, Costanza, et al.
Publicado: (2023)

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study
por: Morsica, Giulia, et al.
Publicado: (2017)

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients
por: Sagnelli, Caterina, et al.
Publicado: (2017)

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
por: Nutt, Jamie, et al.
Publicado: (2017)

Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents
por: Bartolini, Barbara, et al.
Publicado: (2017)

The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
por: Caputo, Valeria, et al.
Publicado: (2020)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models
por: Brombin, Chiara, et al.
Publicado: (2022)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Docking Studies of Pakistani HCV NS3 Helicase: A Possible Antiviral Drug Target
por: Fatima, Kaneez, et al.
Publicado: (2014)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes
por: Costa, Vanessa D., et al.
Publicado: (2019)

Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2012)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection
por: Sillanpää, Maarit, et al.
Publicado: (2009)

Correction: Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2013)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Therapeutic Potential of Antiviral Peptides against the NS2B/NS3 Protease of Zika Virus
por: Hossain, Md. Shahadat, et al.
Publicado: (2023)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

HCV NS3 Blocking Effect on IFN Induced ISGs Like Viperin and IL28 With and Without NS4A
por: Khanlari, Zahra, et al.
Publicado: (2014)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

An Antiviral Peptide from Alopecosa nagpag Spider Targets NS2B–NS3 Protease of Flaviviruses
por: Ji, Mengyao, et al.
Publicado: (2019)

Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches
por: Ikram, Aqsa, et al.
Publicado: (2018)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_16aequt70fcl07ptgnehelsici